These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 28568244)
1. The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myeloma. Ghosh T; Gonsalves WI; Jevremovic D; Dispenzieri A; Dingli D; Timm MM; Morice WG; Kapoor P; Kourelis TV; Lacy MQ; Hayman SR; Buadi FK; Leung N; Go RS; Lin Y; Russell SJ; Lust JA; Zeldenrust SR; Warsame R; Hwa YL; Kyle RA; Gertz MA; Vincent Rajkumar S; Kumar SK Am J Hematol; 2017 Sep; 92(9):E507-E512. PubMed ID: 28568244 [TBL] [Abstract][Full Text] [Related]
2. Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy. Tschautscher MA; Jevremovic D; Rajkumar V; Dispenzieri A; Lacy MQ; Gertz MA; Buadi FK; Dingli D; Hwa YL; Fonder AL; Hobbs MA; Hayman SR; Zeldenrust SR; Lust JA; Russell SJ; Leung N; Kapoor P; Go RS; Lin Y; Gonsalves WI; Kourelis T; Warsame R; Kyle RA; Kumar SK Am J Hematol; 2019 Jul; 94(7):751-756. PubMed ID: 30945330 [TBL] [Abstract][Full Text] [Related]
3. Old and new immunophenotypic markers in multiple myeloma for discrimination of responding and relapsing patients: The importance of "normal" residual plasma cell analysis. Pojero F; Casuccio A; Parrino MF; Cardinale G; Colonna Romano G; Caruso C; Gervasi F Cytometry B Clin Cytom; 2015; 88(3):165-82. PubMed ID: 25529228 [TBL] [Abstract][Full Text] [Related]
4. Circulating plasma cells in newly diagnosed symptomatic multiple myeloma as a possible prognostic marker for patients with standard-risk cytogenetics. Vagnoni D; Travaglini F; Pezzoni V; Ruggieri M; Bigazzi C; Dalsass A; Mestichelli F; Troiani E; Falcioni S; Mazzotta S; Natale A; Angelini M; Ferretti S; Angelini S; Galieni P Br J Haematol; 2015 Aug; 170(4):523-31. PubMed ID: 26010293 [TBL] [Abstract][Full Text] [Related]
5. The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma. Gonsalves WI; Timm MM; Rajkumar SV; Morice WG; Dispenzieri A; Buadi FK; Lacy MQ; Dingli D; Leung N; Kapoor P; Kyle RA; Gertz MA; Kumar SK Leuk Res; 2016 May; 44():32-9. PubMed ID: 26994849 [TBL] [Abstract][Full Text] [Related]
6. Enhancing the R-ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells. Gonsalves WI; Jevremovic D; Nandakumar B; Dispenzieri A; Buadi FK; Dingli D; Lacy MQ; Hayman SR; Kapoor P; Leung N; Fonder A; Hobbs M; Hwa YL; Muchtar E; Warsame R; Kourelis TV; Russell S; Lust JA; Lin Y; Go RS; Siddiqui MA; Kyle RA; Gertz MA; Rajkumar SV; Kumar SK Am J Hematol; 2020 Mar; 95(3):310-315. PubMed ID: 31867775 [TBL] [Abstract][Full Text] [Related]
11. The prognostic impact of multiparameter flow cytometry immunophenotyping and cytogenetic aberrancies in patients with multiple myeloma. Guo J; Su J; He Q; Li X; Zhao Y; Gu S; Fei C; Chang C Hematology; 2016 Apr; 21(3):152-61. PubMed ID: 25860485 [TBL] [Abstract][Full Text] [Related]
12. The Effect of Suppressed Levels of Uninvolved Immunoglobulins on the Prognosis of Symptomatic Multiple Myeloma. Sarı M; Sarı S; Nalçacı M Turk J Haematol; 2017 Jun; 34(2):131-136. PubMed ID: 27795224 [TBL] [Abstract][Full Text] [Related]
13. The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment. Muchtar E; Jevremovic D; Dispenzieri A; Dingli D; Buadi FK; Lacy MQ; Gonsalves W; Hayman SR; Kapoor P; Leung N; Russell S; Lust JA; Lin Y; Go RS; Chakraborty R; Zeldenrust S; Kumar SK; Kyle RA; Rajkumar SV; Gertz MA Blood; 2017 Jan; 129(1):82-87. PubMed ID: 27729322 [TBL] [Abstract][Full Text] [Related]
14. Plasma cell growth fraction using Ki-67 antigen expression identifies a subgroup of multiple myeloma patients displaying short survival within the ISS stage I. Gastinne T; Leleu X; Duhamel A; Moreau AS; Franck G; Andrieux J; Lai JL; Coiteux V; Yakoub-Agha I; Bauters F; Harousseau JL; Zandecki M; Facon T; Eur J Haematol; 2007 Oct; 79(4):297-304. PubMed ID: 17692103 [TBL] [Abstract][Full Text] [Related]
15. Role of interleukin 16 in multiple myeloma. Atanackovic D; Hildebrandt Y; Templin J; Cao Y; Keller C; Panse J; Meyer S; Reinhard H; Bartels K; Lajmi N; Sezer O; Zander AR; Marx AH; Uhlig R; Zustin J; Bokemeyer C; Kröger N J Natl Cancer Inst; 2012 Jul; 104(13):1005-20. PubMed ID: 22745469 [TBL] [Abstract][Full Text] [Related]
16. Higher Decorin Levels in Bone Marrow Plasma Are Associated with Superior Treatment Response to Novel Agent-Based Induction in Patients with Newly Diagnosed Myeloma - A Retrospective Study. Huang SY; Lin HH; Yao M; Tang JL; Wu SJ; Hou HA; Chou WC; Chou SC; Hsu SC; Ko BS; Lu HY; Tsay W; Tien HF PLoS One; 2015; 10(9):e0137552. PubMed ID: 26379028 [TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of plasma cell propidium iodide and annexin-V indices and their mutual ratio in multiple myeloma. Scudla V; Ordeltova M; Minarik J; Dusek L; Zemanova M; Bacovsky J Neoplasma; 2006; 53(3):213-8. PubMed ID: 16652190 [TBL] [Abstract][Full Text] [Related]
18. Multiple myeloma patients with low proportion of circulating plasma cells had similar survival with primary plasma cell leukemia patients. An G; Qin X; Acharya C; Xu Y; Deng S; Shi L; Zang M; Sui W; Yi S; Li Z; Hao M; Feng X; Jin F; Zou D; Qi J; Zhao Y; Tai YT; Wang J; Qiu L Ann Hematol; 2015 Feb; 94(2):257-64. PubMed ID: 25231928 [TBL] [Abstract][Full Text] [Related]
19. The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients. Paiva B; Vidriales MB; Mateo G; Pérez JJ; Montalbán MA; Sureda A; Montejano L; Gutiérrez NC; García de Coca A; de las Heras N; Mateos MV; López-Berges MC; García-Boyero R; Galende J; Hernández J; Palomera L; Carrera D; Martínez R; de la Rubia J; Martín A; González Y; Bladé J; Lahuerta JJ; Orfao A; San-Miguel JF; Blood; 2009 Nov; 114(20):4369-72. PubMed ID: 19755674 [TBL] [Abstract][Full Text] [Related]
20. Adverse prognostic impact of bone marrow microvessel density in multiple myeloma. Lee N; Lee H; Moon SY; Sohn JY; Hwang SM; Yoon OJ; Youn HS; Eom HS; Kong SY Ann Lab Med; 2015 Nov; 35(6):563-9. PubMed ID: 26354343 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]